Medical Doctor Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Dylan Schumacher

Sports Medicine Warrensburg, MO Medical Doctor

NPI 1053931923 CMS profile 11633753

407 E Russell Ave Bldg C, Warrensburg, MO 64093

Open in the dashboard

General payments

$1,601

94 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dylan Schumacher of Warrensburg, MO is reported in the CMS Open Payments database as having received $1,601 across 94 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,282 77
2024 General $319 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dylan Schumacher
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Dylan Schumacher were reported at $1,282. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Dylan Schumacher Sports Medicine median Middle half National median
2019 $0 $119 $35–$362 $163
2020 $0 $77 $24–$275 $114
2021 $0 $104 $28–$340 $132
2022 $0 $94 $31–$272 $149
2023 $0 $91 $34–$271 $160
2024 $319 $126 $38–$294 $164
2025 $1,282 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Pfizer Inc. $275 26 payments
  2. AstraZeneca Pharmaceuticals LP $245 13 payments
  3. AbbVie, Inc. $185 10 payments
  4. Lilly USA, LLC $155 10 payments
  5. Esperion Therapeutics, Inc. $99 1 payment
  6. Radius Health, Inc. $83 3 payments
  7. Vertex Pharmaceuticals Incorporated $81 4 payments
  8. Merck Sharp & Dohme Corporation $71 4 payments
  9. Novo Nordisk Inc $67 4 payments
  10. Axsome Therapeutics, Inc. $60 3 payments
  11. Other $279 16 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $1,601 94 payments
Products named General payments · program years 2024–2025
  1. AIRSUPRA $230 12 payments
  2. NURTEC ODT $218 23 payments
  3. ZAVZPRET $166 19 payments
  4. ZEPBOUND $141 9 payments
  5. QULIPTA $116 5 payments
  6. MOUNJARO $112 7 payments
  7. NEXLETOL $99 1 payment
  8. Tymlos $83 3 payments
  9. GARDASIL 9 $71 4 payments
  10. CAPVAXIVE $71 4 payments
  11. Other $980 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

391

Median for Family Medicine: 130

Drug cost

$3,566

Median for Family Medicine: $5,773

Branded share of claims

7.7%

Median for Family Medicine: 16%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 11 $738
Atorvastatin Calcium Generic 56 $412
Losartan Potassium Generic 36 $303
Rosuvastatin Calcium Generic 32 $300
Pantoprazole Sodium Generic 19 $295
Gabapentin Generic 20 $281
Potassium Chloride Generic 15 $272
Fluticasone Propionate Generic 13 $176
Testosterone Cypionate Generic 12 $131
Levothyroxine Sodium Generic 24 $120

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 699 Part D prescribers listed as Family Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $40
$40 — —
Tymlos
  • Radius Health, Inc. $32
$32 — —
RYBELSUS
  • Novo Nordisk Inc $25
$25 — —
Leqembi
  • Eisai Inc. $23
$23 — —
NURTEC ODT
  • PFIZER INC. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

94 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record